Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years.

ABSTRACT: A regulatory framework allowing legal access to medicinal cannabis (MC) products has operated in Australia since November 2016. MC prescribing by healthcare practitioners (HCPs) is primarily conducted through the Special Access Scheme - Category B (SAS-B) pathway, through which prescribers apply to the Therapeutic Goods Administration (TGA-the federal regulator) for approval to prescribe a category of product to an individual patient suffering from a specific indication. The dataset collected by the TGA provides a unique opportunity to examine MC prescribing trends over time in the Australian population. Here we analysed this TGA SAS-B dataset since inception with respect to age, gender, product type (e.g., oil, flower, etc.), CBD content, indication treated, and prescriber location. Resul

SUBMITTER: MacPhail SL 

PROVIDER: S-EPMC9127064 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature